Suppr超能文献

自体造血干细胞移植后大颗粒淋巴细胞的扩增。

Expansion of large granular lymphocytes after autologous hematopoietic stem cell transplantation.

机构信息

Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.

Department of Clinical Laboratory, The University of Tokyo Hospital, Tokyo, Japan.

出版信息

Int J Hematol. 2023 Jun;117(6):839-844. doi: 10.1007/s12185-023-03540-y. Epub 2023 Feb 11.

Abstract

Expansion of large granular lymphocytes (LGLs) is sometimes observed in allogeneic hematopoietic stem cell transplantation (HSCT) recipients, and is reported to be associated with a favorable transplant outcome. LGLs are also observed after autologous HSCT, but their clinical implications have not been well investigated. We retrospectively reviewed peripheral blood smears of consecutive autologous HSCT recipients. LGL lymphocytosis was defined as the observation of LGLs in the peripheral blood (> 20% white blood cells) in at least two consecutive blood tests. We evaluated the clinical impact of LGL lymphocytosis on autologous HSCT recipients. LGL lymphocytosis was observed in 18 of 197 patients (9.1%) who received autologous HSCT, at a median of 49 days after transplantation, with a median duration of 120.5 days. Incidence of cytomegalovirus reactivation was significantly higher in patients with LGL lymphocytosis than those without (16.7% vs. 3.3%, p = 0.038). No significant difference in survival rates was observed between groups (3 year OS 90.9% vs. 90.5%, p = 0.793 for lymphoma; 100 vs. 92.4%, p = 0.328 for myeloma). LGL lymphocytosis was observed in almost 10% of autologous HSCT recipients. In contrast to allogeneic HSCT, the duration of LGL was shorter and no significant improvement in survival was observed.

摘要

大颗粒淋巴细胞(LGL)扩增在异基因造血干细胞移植(HSCT)受者中有时会观察到,并与良好的移植结果相关。自体 HSCT 后也会观察到 LGL,但它们的临床意义尚未得到充分研究。我们回顾性分析了连续接受自体 HSCT 的受者的外周血涂片。LGL 淋巴细胞增多症定义为在外周血中观察到 LGL(白细胞>20%),至少连续两次血液检查。我们评估了 LGL 淋巴细胞增多症对自体 HSCT 受者的临床影响。在 197 例接受自体 HSCT 的患者中,有 18 例(9.1%)观察到 LGL 淋巴细胞增多症,中位数为移植后 49 天,中位数持续时间为 120.5 天。与无 LGL 淋巴细胞增多症的患者相比,有 LGL 淋巴细胞增多症的患者巨细胞病毒再激活的发生率显著更高(16.7%比 3.3%,p=0.038)。两组的生存率无显著差异(淋巴瘤 3 年 OS 90.9%比 90.5%,p=0.793;骨髓瘤 100%比 92.4%,p=0.328)。LGL 淋巴细胞增多症在近 10%的自体 HSCT 受者中观察到。与异基因 HSCT 不同,LGL 的持续时间较短,且未观察到生存率的显著改善。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6fdb/10225362/1259fb50eaa2/12185_2023_3540_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验